FDA Gives Priority Review Status to Bristol Myers Squibb’s sNDA for Krazati Combo in Colorectal Cancer

The FDA assigned the supplemental new drug application for Krazati (adagrasib) plus cetuximab in patients with locally advanced or metastatic colorectal cancer with a Prescription Drug User Fee Act goal date of June 21, 2024.

Source link
#FDA #Priority #Review #Status #Bristol #Myers #Squibbs #sNDA #Krazati #Combo #Colorectal #Cancer